Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Cash from Investing Activities (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Cash from Investing Activities for 7 consecutive years, with -$394.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Investing Activities fell 675.19% to -$394.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$521.1 million, a 28.95% decrease, with the full-year FY2025 number at -$521.1 million, down 28.95% from a year prior.
  • Cash from Investing Activities was -$394.4 million for Q4 2025 at Kymera Therapeutics, down from -$235.3 million in the prior quarter.
  • In the past five years, Cash from Investing Activities ranged from a high of $81.8 million in Q2 2022 to a low of -$394.4 million in Q4 2025.
  • A 5-year average of -$43.2 million and a median of $21.8 million in 2023 define the central range for Cash from Investing Activities.
  • Peak YoY movement for Cash from Investing Activities: tumbled 1604.74% in 2021, then surged 283.72% in 2025.
  • Kymera Therapeutics' Cash from Investing Activities stood at -$68.0 million in 2021, then grew by 26.98% to -$49.7 million in 2022, then soared by 138.16% to $19.0 million in 2023, then skyrocketed by 261.8% to $68.6 million in 2024, then tumbled by 675.19% to -$394.4 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Cash from Investing Activities are -$394.4 million (Q4 2025), -$235.3 million (Q3 2025), and $60.0 million (Q2 2025).